Rafael Holdings, Inc. Total Liabilities
Rafael Holdings, Inc. total liabilities. Based on the latest financial reports, Rafael Holdings, Inc. (RFL) has total liabilities worth $16.06 Million USD as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Rafael Holdings, Inc. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rafael Holdings, Inc. (2016–2025)
Total liabilities of Rafael Holdings, Inc. from 2016 to 2025. This chart illustrates how Rafael Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore RFL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Rafael Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Rafael Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dutaland Bhd
KLSE:3948
|
Malaysia | RM89.33 Million |
|
Biome Australia Ltd
AU:BIO
|
Australia | AU$6.25 Million |
|
Melhus Sparebank
OL:MELG
|
Norway | Nkr10.35 Billion |
|
Fanhua Inc.
NASDAQ:AIFU
|
USA | $1.06 Billion |
|
Centrepoint Alliance Ltd
AU:CAF
|
Australia | AU$24.86 Million |
|
Envoy Medical Inc.
NASDAQ:COCH
|
USA | $20.65 Million |
|
Traphaco JSC
VN:TRA
|
Vietnam | ₫837.63 Billion |
|
Decibel Cannabis Company Inc
V:DB
|
Canada | CA$82.85 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Rafael Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RFL asset base.
Liquidity & Leverage Metrics
Rafael Holdings, Inc. Total Liabilities Ratios Explained
Rafael Holdings, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.06 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rafael Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rafael Holdings, Inc. (2016–2025)
The table below shows the annual total liabilities of Rafael Holdings, Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | $15.74 Million | +48.84% |
| 2024-07-31 | $10.57 Million | +380.64% |
| 2023-07-31 | $2.20 Million | -89.58% |
| 2022-07-31 | $21.11 Million | +21.69% |
| 2021-07-31 | $17.35 Million | +198.18% |
| 2020-07-31 | $5.82 Million | -66.52% |
| 2019-07-31 | $17.38 Million | +1182.58% |
| 2018-07-31 | $1.35 Million | -94.38% |
| 2017-07-31 | $24.13 Million | +55.69% |
| 2016-07-31 | $15.50 Million | -- |
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells… Read more